Brigatinib first to offer over 1-year control of ALK-positive lung cancer post-crizotinib

(University of Colorado Anschutz Medical Campus) Results of a multi-center, 222-person phase 2 clinical trial of the next-generation ALK inhibitor, brigatinib at 180mg/day, used after failure of crizotinib showed a 54 percent response rate and 12.9 month progression-free survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news